Clinical Trial Update: SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating SBRT combined with Avelumab for non-small cell lung cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Andrew Sharabi | Conditions: Early Stage Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-08-09